Markets:

Overview

News

Currencies

International

Treasuries

Insmed Incorporated - Common Stock (NQ:INSM)

204.00 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Insmed Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗

December 03, 2025

One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms.

Via The Motley Fool

Topics Regulatory Compliance

PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗

December 03, 2025

PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down.

Via The Motley Fool

Topics Regulatory Compliance

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗

December 03, 2025

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares?

Via The Motley Fool

Topics Regulatory Compliance

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

A Preview Of Insmed's Earnings ↗

October 29, 2025

Via Benzinga

Analyst Expectations For Insmed's Future ↗

October 02, 2025

Via Benzinga

Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results

December 03, 2025

December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an...

Via MarketMinute

30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks ↗

November 30, 2025

Stanley Druckenmiller is considered one of the greatest investors of all time.

Via The Motley Fool

Topics Artificial Intelligence

Billionaire Stanley Druckenmiller Just Bet Big on This Hot IPO Stock. Is It a Buy? ↗

November 23, 2025

This online ticket marketplace debuted in September, but has struggled thus far.

Via The Motley Fool

Topics ETFs Initial Public Offering Regulatory Compliance

Peering Into Insmed Inc's Recent Short Interest ↗

November 18, 2025

Via Benzinga

Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves ↗

November 14, 2025

Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation.

Via Benzinga

If You Invested $1000 In Insmed Stock 10 Years Ago, You Would Have This Much Today ↗

November 14, 2025

Via Benzinga

This Investor Sold $1.9 Million in AMSC Stock Ahead of 35% Post-Earnings Crash ↗

November 10, 2025

This Investor Sold $1.9 Million in AMSC Stock Ahead of 35% Post-Earnings Crash

Via The Motley Fool

Topics Regulatory Compliance

Essex Investment Buys $7.1 Million Globalstar Stake as Revenue Hits Record High ↗

November 09, 2025

Essex Investment Buys $7.1 Million Globalstar Stake as Revenue Hits Record High

Via The Motley Fool

Topics Regulatory Compliance

Here's How Much $1000 Invested In Insmed 10 Years Ago Would Be Worth Today ↗

October 31, 2025

Via Benzinga

Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday ↗

October 30, 2025

Via Benzinga

Insmed Catapults While IBD 50's Argenx Creeps Higher On Bullish Reports ↗

October 30, 2025

Insmed stock surged early Thursday as Argenx stock rose more moderately. The top-notch biotech companies beat third-quarter calls.

Via Investor's Business Daily

Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday? ↗

October 30, 2025

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome...

Via Benzinga

Topics Economy

Here's How Much $1000 Invested In Insmed 5 Years Ago Would Be Worth Today ↗

October 23, 2025

Via Benzinga

This Is What Whales Are Betting On Insmed ↗

October 15, 2025

Via Benzinga

Here's How Much $1000 Invested In Insmed 10 Years Ago Would Be Worth Today ↗

October 07, 2025

Via Benzinga

6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner ↗

September 30, 2025

Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.

Via Benzinga

Spotlight on Insmed: Analyzing the Surge in Options Activity ↗

September 25, 2025

Financial giants have made a conspicuous bearish move on Insmed. Our analysis of options history for Insmed (NASDAQ: INSM) revealed 29 unusual trades.

Via Benzinga

Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today ↗

September 22, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

September 09, 2025

Via Benzinga

Deep Dive Into Insmed Stock: Analyst Perspectives (26 Ratings) ↗

September 03, 2025

Via Benzinga

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It ↗

September 02, 2025

The company sells Tyvaso, a treatment for lung diseases. On Tuesday, Tyvaso showed promise, again, in a chronic condition.

Via Investor's Business Daily

Israel Englander's Millennium Goes All-In On Crypto And Healthcare While Rebalancing Big Tech Bets: Bitcoin ETF And Palantir Stakes Soar In Q2 ↗

August 27, 2025

Millennium Management's Q2 2025 13F reveals big bets on crypto (IBIT, PLTR) & healthcare (EW, INSM), with tech rebalancing. Read key changes!

Via Benzinga

Topics ETFs

Why Electromed Stock Jumped 12% After-Hours: A Rival’s Weakness And A New Drug Tailwind ↗

August 26, 2025

The after-hours surge came as management pointed to hospital market share gains from a distracted competitor and rising bronchiectasis awareness following Insmed’s FDA-approved drug launch.

Via Stocktwits

Topics Earnings

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.